Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03194750 · ClinicalTrials.gov registry record · NA
Ultrasound Assessment of Volume in Patients on Continuous Dialysis
A NA study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT03194750 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 6 participants.
The verdict
NCT03194750, a NA study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
Renal failure and resuscitation measures in critically ill patients can result in fluid overload. Fluid overload in renal failure patients can cause harmful effects like pulmonary edema, anasarca and congestive cardiac failure exacerbations among other complications. These have been associated with increased time on the ventilator, increased length of stay in the ICU, and higher overall mortality for patients requiring dialysis in the ICU. The current standard of care for adjusting fluid removal rates in patients on continuous renal replacement therapy relies on clinical judgement. Clinicians take into account factors like the patient's condition, vasopressor requirements, kidney function, total intake and outputs, vital signs, and physical examination findings when making daily changes to fluid removal rates on dialysis machines. Such assessment is highly subjective and can be imprecise/inaccurate leading to hypotension and hemodynamic instability in a critically ill patient. Use of conventional ultrasound by physicians to assess volume status using compressibility of the inferior vena cava has been shown to be a reliable predictor of volume status and can help guide therapy. Such use makes bedside volume assessment a non-invasive, rapid, repeatable point of care tool that can provide objective data to guide fluid removal determine velocity of fluid removal and help identify patients at risk of hypotension and hemodynamic instability during the process of fluid removal. Apart from rare possible local allergic reactions to ultrasound jelly and transient local discomfort, the disadvantages are minimal. Ultrasonography has been considered a safe imaging modality. This protocol will measure inferior vena cava compressibility using the General Electric VScan with Dual Probe, which has FDA approval for abdominal and vascular imaging in humans.
Interventions
- OTHER Share ultrasound measurement of IVC collapsibility to Nephrology Attending
- OTHER Do not share ultrasound measurement of IVC collapsibility to Nephrology Attending
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-06-01 |
| Est. Completion | 2023-09-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03194750
The ClinicalTrials.gov registry entry for NCT03194750 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Share ultrasound measurement of IVC collapsibility to Nephrology Attending is the first listed.
NCT03194750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03194750 about?
NCT03194750 is a clinical study titled "Ultrasound Assessment of Volume in Patients on Continuous Dialysis". Renal failure and resuscitation measures in critically ill patients can result in fluid overload. Fluid overload in renal failure patients can cause harmful effects like pulmonary edema, anasarca and congestive cardiac failure exacerbations among other complications. These have been associated with ...
What is the current status of trial NCT03194750?
This trial is currently completed. It is a NA study. The enrollment target is 6 participants. The study started on 2016-06-01. Estimated completion is 2023-09-07.
What interventions are being tested in trial NCT03194750?
The interventions under investigation include: Share ultrasound measurement of IVC collapsibility to Nephrology Attending (OTHER), Do not share ultrasound measurement of IVC collapsibility to Nephrology Attending (OTHER).
Who is sponsoring clinical trial NCT03194750?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.